CNS Organoid Neuropharmacological Analysis
Key Dates
Due Date
-
Posted Date
-
Agency & Value
Agency
FDA OFFICE OF ACQ GRANT SVCS
Contract Value
Not provided
Codes & Classification
Solicitation Number
75F40126Q134171
NAICS
541380 - Testing Laboratories and Services
Classification Code
B537
Additional Details
Documents2
The Food and Drug Administration (FDA), operating under the Department of Health and Human Services, has issued a combined synopsis/solicitation for CNS Organoid Neuropharmacological Analysis. This procurement seeks specialized testing laboratory services, as classified under NAICS code 541380, to support neuropharmacological research utilizing central nervous system (CNS) organoids. The intended scope of work involves advanced analytical testing and evaluation of CNS organoids, which are three-dimensional cellular models used to study neurological function and drug response. The outcomes of this procurement are expected to enhance the FDA’s scientific understanding of neuropharmacological effects, potentially informing regulatory decisions and advancing public health objectives.
The solicitation is managed by the FDA Office of Acquisition and Grant Services, a federal office responsible for overseeing procurement activities within the agency. The place of performance is within the United States, and the opportunity is classified under Product Service Code B537, indicating a focus on scientific and laboratory services related to biological studies.
Key requirements for this contract include the provision of laboratory testing services that meet rigorous scientific standards, with deliverables likely encompassing detailed analytical reports, data sets, and technical support for CNS organoid studies. Contractors must demonstrate expertise in neuropharmacology, laboratory testing, and the handling of organoid models. The procurement is structured as a combined synopsis/solicitation, streamlining the process for interested vendors to submit proposals.
The notice is currently active, with a posting date of June 22, 2026, and a response deadline of July 6, 2026. Interested parties should review the attached documents available via the SAM.gov opportunity link for comprehensive requirements and submission instructions. The primary point of contact for this solicitation is Nick Sartain, who can be reached at [email protected] or by phone at 301-796-1988.
Contractors evaluating this opportunity should note the federal nature of the procurement, the scientific and technical focus, and the expectation for high-quality laboratory services. Elements such as the scope of neuropharmacological analysis, the use of CNS organoids, and the requirement for robust testing capabilities will remain central throughout the contract lifecycle. No set-aside requirements or special considerations are specified in the provided information, but further details may be available in the solicitation attachments.
For more information and to access the solicitation documents, visit the official SAM.gov opportunity page at: https://sam.gov/opp/b04f4cdb933f431ea11a6dbdf20a8dd9/view.